Clinical Research Papers:

Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in penile cancer

Sheng Zhang _, Wenfeng Li and Fei Liang

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:48600-48606. https://doi.org/10.18632/oncotarget.9375

Metrics: PDF 1788 views  |   HTML 5588 views  |   ?  


Sheng Zhang1, Wenfeng Li2 and Fei Liang3

1 Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

2 Department of Medical Oncology, Qingdao University Medical Center, Qingdao, China

3 Clinical Statistics Center, Shanghai Cancer Center, Fudan University, Shanghai, China

Correspondence to:

Sheng Zhang, email:

Keywords: penile cancer; PET/CT; clinical impact

Received: February 08, 2016 Accepted: May 09, 2016 Published: May 14, 2016



This study investigated the value of Fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET)/computed tomography (CT) imaging in the management of patients with advanced penile cancer.

Patients and Methods

Between January 2009 and August 2012, 48 patients with penile cancer at our center underwent FDG-PET/CT after CT (n=39) or magnetic resonance imaging (MRI; n=9). The accuracy of FDG-PET/CT was assessed with both organ-based and patient-based analyses. FDG-PET/CT findings were validated by either biopsy or serial CT/MRI. Clinician questionnaires performed before and after FDG-PET/CT evaluated whether the scan results affected management.


One hundred fifteen individual lesions were evaluable in 42 patients for the organ-based analysis. Overall sensitivity was 85% and specificity was 86%. In the patient-based analysis, overall sensitivity and specificity were 82% and 93%, respectively. Pre- and post-PET surveys showed that FDG-PET/CT detected more malignant diseases than CT/MRI in 33% patients. Planned treatments were changed in 57% patients after FDG-PET/CT scan.


FDG-PET/CT has good sensitivity and specificity in the detection of metastatic penile cancer. It provides more diagnostic information to enhance clinical management than CT/MRI.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9375